Compare Medpace Holdings Inc (MEDP) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Standard Lithium Ltd — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Standard Lithium Ltd trades at $2.17 (market cap $523.89M). The key difference: Medpace Holdings Inc is far larger — about 28.8× Standard Lithium Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| MEDP | SLI | |
|---|---|---|
Market Cap | $15.08B | $523.89M |
Sector | Technology | Basic Materials |
52-Week High | $620.59 | $5.65 |
52-Week Low | $308.88 | $2.15 |
Enterprise Value | $14.55B | $383.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Standard Lithium (SLI) trades at $2.15, down 4.87% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $48.40 million for 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus remains unanimously bullish with three buy ratings, citing progress toward a final investment decision in 2026.
The investment case hinges on successful project execution, with upside potential from lithium demand and federal funding, but risks include sustained cash burn and delays. The stock's current valuation at 1.52 times book value may attract value investors, yet profitability challenges and bearish technical trends warrant caution amid high operational expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
